Skip to content
银诺医药 INNOGEN
HKEX 02591
CareersContact
Company

Company

View overview →
Vision & mission→Leadership→Our history→Institutional investors→
Science & pipeline

Science & pipeline

View overview →
Development pipeline→Clinical evidence→Protein platform→Development & manufacturing→AI-assisted discovery→Research library→
Medicine resources
Investors

Investors

Investor overview →
Financial reports→Announcements & circulars→Governance→Listing documents→Corporate communications→IR contact→
News
EN中文
Company→Science & pipeline→Medicine resources→Investors→News→
CareersContact
← About Innogen

Institutional investors

Profiles published in 2022.

BioTrack Capital

Profile→

Dyee Capital

Profile→

China Everbright Limited

Profile→

Hongtai Fund

Profile→

China Growth Capital

Profile→

Guoke Jiahe (Beijing) Investment Management

Profile→

Korea Investment Partners (KIP)

Profile→

Langmafeng Venture Capital

Profile→

Shanghai Pudong Investment Holdings (Group) Co., Ltd.

Profile→

Cowin Capital

Profile→

Xiaochi Capital

Profile→

Youshan Capital (优山资本)

Profile→

V Star Capital

Profile→

Yuanhui Chuangyi

Profile→

CICC Capital

Profile→

Centurium Capital

For current shareholding information, see our investor disclosures.

银诺医药 INNOGEN

Focused on diabetes and metabolic diseases

HKEX 02591
CompanyScience & pipelineMedicine resourcesInvestorsNewsCareersContact

Contact Innogen

Follow Innogen on WeChat
QR code to follow Innogen on WeChat

Scan with WeChat.

Save QR code
info@innogenpharm.com ↗

399 Haiyang West Road, Pudong, Shanghai
21st Floor, Qiantan Times Square

Adverse events, complaints and inquiries400-004-0060
Drug_safety.postmarketing@innogenpharm.com ↗
© 2026 Innogen
Public security filing: 31011502013055 ↗ · ICP: 沪ICP备16021048号-1 ↗